Genmab A/S is a leading pharmaceutical company based in Denmark, specializing in antibody therapeutics for cancer treatment. The company has a medium risk assessment with an ESG score of 20.4. Genmab's innovative proprietary antibody technologies, including DuoBody and HexaBody, have led to successful partnerships with major companies like Johnson & Johnson. Darzalex, their flagship product, is considered the standard of care for multiple myeloma. Genmab also offers Tepezza, Kesimpta, Rybrevant, Tivdak, and Epkinly for various oncologic indications. With a strong pipeline of candidates, Genmab is dedicated to advancing sustainable healthcare solutions.